Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration

• Main Authors: Siqi Wang (Author), Yawen Yu (Author), Aiping Wang (Author), Xinliu Duan (Author), Yuchen Sun (Author), Liangxiao Wang (Author), Liuxiang Chu (Author), Yanan Lv (Author), Nan Cui (Author), Xuesong Fan (Author), Chunjie Sha (Author), Lixiao Xu (Author), Kaoxiang Sun (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Temozolomide (TMZ) is the first-line drug for glioblastoma (GBM), but it is limited in clinical use due to the drug resistance, poor brain targeting, and side effects. Temozolomide hexadecyl ester (TMZ16e), a TMZ derivative with high lipophilicity, membrane permeability, and high anti-...